Here are 1-2 brief analogies for Rani Therapeutics:

• Rani Therapeutics is like the "Impossible Foods for injectable biologics," aiming to replace traditional injections of complex biologic medicines with easy-to-take oral pills.

• Think of Rani Therapeutics as the "Carvana for drug administration," simplifying the complex and often intimidating process of taking biologic drugs (currently injections) into a convenient, everyday oral pill.

• RaniPill capsule: A platform technology designed to replace injectable biologics with oral dosing.
• RT-101 (octreotide): An orally administered octreotide in Phase I clinical trials for neuroendocrine tumors and acromegaly.
• RT-105 (anti-TNF-alpha antibody): An orally administered anti-TNF-alpha antibody in preclinical studies for psoriatic arthritis.
• RT-102 (parathyroid hormone): An orally administered parathyroid hormone in preclinical studies for osteoporosis.
• RT-109 (human growth hormone): An orally administered human growth hormone in preclinical studies for growth hormone deficiency.
• RT-110 (parathyroid hormone): An orally administered parathyroid hormone in preclinical studies for hypoparathyroidism.
• RT-106 (basal insulin): An orally administered basal insulin in preclinical studies for type 2 diabetes.

Rani Therapeutics (RANI) is a clinical-stage biotherapeutics company focused on developing orally administered biologics. As described, its product candidates are currently in preclinical studies or Phase I clinical trials.

At this stage of development, Rani Therapeutics does not have major commercial customers that purchase its products, as its drug candidates have not yet received regulatory approval for sale or commercialization. Its operations are concentrated on advancing its pipeline through clinical development.

Talat Imran, Chief Executive Officer

Talat Imran was appointed CEO of Rani Therapeutics in June 2021, having previously served as the company's Vice President, Strategy since 2014. His background includes experience as a venture capitalist with healthcare-focused Silicon Valley funds, such as InCube Ventures, LP, and VentureHealth. He also previously held the position of Chief Executive Officer at Venture Web Partners, a web application development firm. Talat is the son of Rani's founder and Executive Chairman, Mir Imran.

Svai Sanford, Chief Financial Officer

Svai Sanford has served as the Chief Financial Officer of Rani Therapeutics Holdings, Inc. since November 2018. He brings over 25 years of accounting, finance, and management experience in the biopharmaceutical and medical device sectors for both public and private companies. Prior to joining Rani, Mr. Sanford held CFO positions at SFJ Pharmaceuticals and VIVUS, Inc., a publicly traded biopharmaceutical company, where he was also Chief Accounting Officer. His experience also includes roles as an executive consultant and interim CFO for pH Pharma and Intuity Medical. He began his career in audit at KPMG LLP, where he earned his certified public accountant license.

Mir Imran, Executive Chairman

Mir Imran is the founder of Rani Therapeutics, which was established in 2012 as a research project within his InCube Labs. A prolific medical inventor, entrepreneur, and venture capitalist, he has founded more than 20 life sciences companies since the late 1970s, with over half of them being acquired or going public. Mr. Imran is particularly recognized for his significant contributions to the development of the world's first FDA-approved Automatic Implantable Cardioverter Defibrillator (ICD). The company responsible for the ICD, Intec Systems, was acquired by Eli Lilly, later spun out as Guidant, and eventually acquired by Boston Scientific for $27.5 billion.

Mir Hashim, Chief Scientific Officer

Mir Hashim serves as the Chief Scientific Officer at Rani Therapeutics. He is the nephew of the company's founder, Mir Imran. Dr. Hashim previously spent 18 years at Glaxo Smith Kline, where he held the position of head of Pharmacology. His expertise encompasses extensive experience in drug discovery and development, international regulatory submissions, international product development, and the in-licensing and out-licensing of drug candidates.

Kate McKinley, Chief Business Officer

Kate McKinley is the Chief Business Officer of Rani Therapeutics. She has over 20 years of experience in the biopharmaceutical industry, including executive leadership and board director roles. Prior to Rani, Ms. McKinley was the CEO and founder of Spark Lifesciences. She also served as CEO and Board Director for Elvar Therapeutics (formerly LSK Biopharma), after holding positions as their Chief Commercial Officer and Chief Business Officer. She began her career at Abbvie Biopharmaceuticals / Abbott Laboratories, where she was Vice President of National Sales in the urology, oncology, and gynecology therapeutic areas.

Key Risks to Rani Therapeutics (RANI)

1. Clinical Development and Regulatory Approval Risk: Rani Therapeutics' future is entirely dependent on the successful completion of clinical trials and obtaining regulatory approvals for its drug candidates and, critically, for its novel RaniPill platform. The majority of drug candidates fail during clinical development due to issues with safety or efficacy, and the probability of success for clinical-stage companies is inherently low. This risk is particularly pronounced as the company's entire pipeline and business model relies on the successful validation of a new and complex drug delivery system for biologics.
2. Technological Validation and Market Acceptance of Oral Biologics Delivery: A significant risk lies in the successful, broad validation and subsequent market acceptance of the RaniPill capsule platform itself. While promising, demonstrating consistent efficacy, safety, and scalability of a novel oral delivery system for a diverse range of biologics across various conditions, and overcoming potential hurdles in physician and patient adoption compared to established injectable therapies, represents a substantial challenge. If the platform fails to deliver on its promise or gain widespread acceptance, it would severely impact the company's long-term viability.

Here are 3-5 expected drivers of future revenue growth for Rani Therapeutics (RANI) over the next 2-3 years:

1. Advancement and Potential Commercialization of Obesity Pipeline: Rani Therapeutics' lead programs in the high-value obesity market, particularly RT-114 and RT-116 (oral semaglutide), are significant drivers. RT-114, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen, has initiated a Phase 1 clinical trial. Successful progression and eventual commercialization of these oral biologic treatments, leveraging the RaniPill platform, are expected to capture substantial market share in the growing obesity sector.
2. Strategic Partnerships and Licensing Agreements: The collaboration and license agreement with Chugai Pharmaceutical for an oral product utilizing the RaniPill platform with Chugai's rare disease antibody is a key revenue driver. This partnership includes an upfront payment and potential success-based technology transfer and development milestones, which could total over $1 billion if Chugai exercises options for additional targets, providing non-dilutive funding and future revenue streams.
3. Expansion and Validation of the RaniPill Platform: The broad applicability and proven efficacy of the RaniPill capsule for oral delivery of biologics are central to future growth. Demonstrating the platform's ability to achieve high bioavailability across multiple molecules is anticipated to attract further partnerships and licensing opportunities across various high-value indications, including immunology.
4. Progression and Approval of Core Pipeline Assets: Beyond the obesity programs, the successful completion of clinical trials and subsequent regulatory approvals for other pipeline candidates, such as RT-102 for osteoporosis and RT-111 for psoriasis, are expected to contribute to revenue growth. Zacks analysts anticipate clinical trial completion and approval for RT-102 and RT-111 in 2027, which would allow Rani Therapeutics to tap into the broader biologics market.

Share Issuance

• In October 2025, Rani Therapeutics completed an oversubscribed private placement that generated gross proceeds of approximately $60.3 million. This involved the issuance of 42,633,337 shares of Class A common stock at $0.48 per share and pre-funded warrants to purchase up to 82,366,667 shares of Class A common stock at $0.4799 per pre-funded warrant.
• In July 2025, Rani Therapeutics executed a registered direct offering with a single institutional investor, resulting in gross proceeds of approximately $3.0 million. This transaction included the sale of 4,354,000 shares of Class A common stock at $0.40 per share and pre-funded warrants to purchase 3,146,000 shares of Class A common stock at $0.3999 per share.
• As part of the October 2025 private placement, Avenue Venture Opportunities Fund converted $6 million of outstanding debt into 12.5 million shares of Class A common stock and received warrants to purchase up to 12.5 million additional shares.

Inbound Investments

• Rani Therapeutics secured approximately $60.3 million in an oversubscribed private placement in October 2025, with financing led by Samsara BioCapital and participation from RA Capital Management, Anomaly, Special Situations Funds, Invus, and Executive Chairman Mir Imran.
• In October 2025, Rani Therapeutics entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co. Ltd. The agreement includes an initial upfront payment of $10.0 million and an expected technology transfer milestone payment of $18.0 million, with a total potential value of up to $1.085 billion including future milestones and royalties.
• The capital raised from the October 2025 private placement and the initial payments from the Chugai collaboration are anticipated to extend the company's cash runway into 2028.

Capital Expenditures

• For the last 12 months as of March 10, 2026, Rani Therapeutics reported capital expenditures of -$119,000.
• In 2024, the company incurred a $3.7 million impairment loss on certain manufacturing assets but also made investments in automation.
• Investments in automation are focused on maintaining competitive cost of goods compared to injectables.